MOMO'S BREAKOUT BOARD

[AAAAMHIM]

NSPX .0025?! DO YOU SEEEEEEEE THE MASSIVE HITS THAT JUST WENT THROUGH ON THE ASK??! ALMOST 4 MILLION SHARES BACK TO BACK TO BACK SMACKS. FLOAT ALMOST LOCKED FOLKS. Ignore the noise. Stop letting rookies compare a FORMER NASDAQ STOCK WITH CANCER PATENTS and a BRAIN cancer DRUG to his basic BLOATED, no PRODUCT having OTC SCAMS!!! Like SERIOUSLY? NSPX IS ABOUT TO BREAK 008s before you know it. READ THE TRADES too many shares have been SOAKED up. MMs cant rattle the pros who own calculators and UNDERSTAND the importance of share structures. It's your last chance for these 0025s.

$NSPX .0025 CAN IT RUN TO OVER $3?  The answer is OF COURSE. NSPX announced a REVERSE split due in DECEMBER and it sent the stock crumbling tight at the bell. USED TO TRADE AT $250 on Nasdaq. A $1.8 BILLION HEDGEFUND THAT STRICTLY INVESTMENTS/stocks on the BIGBOARD with its specialty #BIOTECH LOADED SHARES HEAVY. They loaded 10% of the shares! NSPX is the only OTC STOCK IN THEIR PORTFOLIO! This happened right after their 1st PR in well over a year where they announced a partnership deal with Ridgeway pharmaceutical that could bring them $12 MILLION in REVENUES. These 2 occurrences are why I loaded in the 1st place, it was a smoking gun and when there is smoke there is usually FIRE. NSPX has over 125 million O/S and 150 million A/S. SHARES ARE MAXED. Over 80% of their existence has been on NASDAQ being an OTC stick is foriegn to them, could an uplist to NASDAQ be the reason they are doing the reverse split IN DECEMBER???!

REGARDLESS OF THE REVERSE SPLIT, this share structure is MININSCULE. Name a pharmaceutical company you know trading at 003 with ONLY 150 MILLION A/S. YOU WONT FIND ONE PERIOD, and if you do dont tell anyone just send me a private message so I can load that too.

DO YOU UNDERSTAND THE IMPORTANCE OF SHARE STRUCTURE???!! 99.9999% if traders DON'T. 150 million A/S at 003??!! For a #BIOTECH stock??!! What??! STOP IT.

EVEN DURING THE BLOOD BATH 003s held, everytime the 003 bid was crushed a MASSIVE BID REPLACED the CRUSHED bid ready to steal more shares. I KNOW, REVERSE SPLITS SUCK but it is RARE you find a REVERSE split with a stock with a FLOAT this tiny, add a FORMER NASDAQ STOCK with a PROVEN FDA CLEARED BRAIN CANCER DRUG which the pharmaceutical industry have labeled as the CANCER GRENADE. ITS NOT FANTASY their DRUG has already had numerous RESULTS of treating cancer patients ON THEIR LAST STAGE where everything else failed, this is a FACT. No koolaid needed here. 003?! I GUARANTEE that it will break well above that. IGNORE THE ROOKIES. FOLLOW VETERAN TRADERS WITH PROVEN TRACK RECORDS. This is not magic.

Their drug mispargarin could replace chemotherapy.  

;


$NSPX .0025?! WAS once $250 CANCER PATENT GRANTED NOT PR'ed. UNKNOWN. If you ever heard about $NSPX chances are you heard it from ME. 

https://patents.justia.com/assignee/inspyr-therapeutics-inc ; ;

$NSPX HUGE Merger. NOT PR'D????  
https://globenewswire.com/news-release/2017/09/13/1120305/0/en/Inspyr-Therapeutics-and-Lewis-and-Clark-Pharmaceuticals-Complete-Merger.html ; ;

Only 130 MILLION shares outstanding?  

YOU guys KNOW how pharma stocks run from subs to $$$ ranges. $NSPX has a patent signed a $100 million private financing already received 25 million. Its A lotto for me but I like her. You see on the L2 after .02 is $200, THIN. Only reason its down at this mouth watering price is because it is VERY UNKNOWN. Won't be unknown for long  

This is a little sloppy write up. Just little items I connected together. Trying to simplify the DD.  

$NSPX Secures Patent on Methods of Producing Cancer Targeting  

Inspyr Therapeutics Secures Patent on Methods of Producing Cancer Targeting CompoundsPharmaceutical | Tue 19 Dec 2017Alexandria, Dec. 19 -- Inspyr Therapeutics has secured a patent on methods of producing cancer targeting compounds. Lynch John K, Hutchison Jeff, #$%$ Xiong and Kunnen Kevin developed the invention. The patent application number is 15/232,599. The International Patent Classification codes are C07D 307/93 (20060101), C07C 227/16 (2..  

"INSPYR THERAPEUTICS AND LEWIS AND CLARK PHARMACEUTICALS MERGE"  

"Lewis & Clark Pharma: We have deep expertise in the synthesis, analysis, and early stage development of adenosine receptor-based compounds, with a focus on A2A and A2B antagonists, and A2A agonists. Our proprietary compounds are highly potent and selective, and – most importantly, have molecular properties that enable enhanced distribution in tissue and penetration of human skin – and the opportunity for novel therapies that could address a broad range of large, chronic, underserved diseases:  

A2A/A2B antagonists for a range of tumors, as a mono- or combination therapy, including:  

Solid tumors, e.g., breast, colorectal, melanoma, lung, prostate, bladder  

Hematological malignancies, e.g., multiple myelomas, acute lymphocyte leukemia"  

From the annual report from fiscal year ending December 31, 2016: Our major focus for the next twelve to eighteen months is the (i) development of a clinical protocol for and enrollment into a dose optimization trial of single-agent mipsagargin followed by a clinical trial in patients with advanced HCC, (ii) completion of the non-clinical study of mipsagargin in combination with Nexavar® in liver tumor models (iii) development of a Phase 1b clinical protocol of mipsagargin in combination with Nexavar® in patients with Nexavar® naïve HCC in anticipation of positive non-clinical data, (iv) completion of a nonclinical study of mipsagargin in combination with paclitaxel and in combination with DC101 (Cyramza surrogate antibody) in gastric cancer tumor models, (v) ongoing business development discussions with potential development partners, (vi) evaluation of mipsagargin (single agent and in combination with standard of care) in nonclinical models of other solid tumor types that express PSMA, (vii) evaluate our PSMA-peptide prodrug technology with new linkers and new payloads in non-clinical models, and (viii) explore collaborations utilizing mipsagargin in new, non-clinical solid tumor models with leading researchers in the oncology field.  

Proceeds will be used to advance Inspyr’s clinical development plans and provide for working capital needs. The Company’s entry into the Milost Equity Subscription Agreement Financing Facility (MESA) and the initial tranche of funding is subject to required approvals, final documentation, and customary closing conditions.  

“We are pleased to have reached an agreement on the key investment terms, the first step in securing a solid foundation of capital for Inspyr for the next several years,” said Peter Grebow, Ph.D., Chairman of Inspyr Therapeutics.  

“We are pleased to be a financial partner to Inspyr and look forward to closing the transaction promptly,” said Egerton Forster, Milost Global Inc. Co-found  

NSPX RECENTLY SECURED  
100M in financing from private equity firm, the needle is moving in the right direction.  

"Well...I see that they have started a couple trials involving treatment with sorafenib with mipsigargin as an adjuvant therapy.  
Hmmmmmmmmmmmmmmmmm...they say they are looking for a synergistic effect from the combo. The non pre clinical trial will be used on folks with advanced HCC, so they are looking for arresting progression of the disease. Mipsigargin was a lot better at arresting progression than sorafenib's 2 months. Perhaps together they can arrest progression for a year or more. I suspect that even with progression arrested, many folks will die as a result of the damage the cancer has already caused.  

Hey...the company is moving forward again. Cheers for the new year!!!"  

Can $NSPX run over $3? Its a cancer pharma stock with patents. 1 succesful trial away from $100+ imo. You know how these pharmas go. Hit or miss.  

NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX